Histone demethylase inhibitors
The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase enzymes. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as pancreatic cancer, prostate cancer, breast cancer, bladder cancer, lung cancer, gastric cancer, leukemia and/or melanoma and the like.
1. A compound having the structure of Formula (Ic),
or a pharmaceutically acceptable salt thereof, wherein
R 1 is hydrogen, halogen, or substituted phenyl, wherein a substituent is at least one halogen, haloalkyl, C 1 -C 5 alkyl, C 1 -C 5 alkoxy, alkylaminoalkoxy, or alkoxyalkoxy;
R 2 is hydrogen, C 1 -C 5 alkyl, mono- or bi-cyclic C 7 -C 12 carbocyclylalkyl, or substituted arylalkyl, wherein a substituent is at least one halogen, haloalkyl, haloalkoxy, haloaryl, alkoxy, aryl, or aryloxy;
R 3 is hydrogen;
R 4 is hydrogen, halogen, —CN, or C 1 -C 4 alkyl, wherein when R 4 is C 1 -C 4 alkyl, said C 1 -C 4 alkyl is optionally substituted with at least one halogen.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is mono- or bi-cyclic C 7 -C 12 carbocyclylalkyl.
3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 2 is optionally substituted naphthylalkyl or dihydroindylalkyl.
4. The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein the naphthylalkyl is naphthylmethyl, naphthylethyl, tetrahydronaphthylmethyl, tetrahydronaphthylethyl, chloronaphthylmethyl, fluoronaphthylmethyl, chloronaphthylethyl, fluoronaphthylethyl, propylnaphthylmethyl, or propylnaphthylethyl.
5. The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein the dihydroindyl of the dihydroindylalkyl is substituted with halogen or C 1 -C 4 alkyl.
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is substituted arylalkyl, wherein a substituent is at least one halogen, haloalkyl, C 1 -C 5 alkyl, C 1 -C 5 alkoxy, alkylaminoalkoxy, or alkoxyalkoxy.
7. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein the halogen is chloro or fluoro.
8. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein the substituted arylalkyl is substituted phenylalkyl.
9. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein the substituted phenylalkyl is chlorophenylmethyl, chlorophenylethyl, chlorophenylmethylpropyl, dichlorophenylmethyl, dichlorophenylethyl, chloro-fluorophenylmethyl, (fluoro)methylphenylmethyl, trifluoromethylphenylethyl, (trifluoromethyl)chlorophenylmethyl, (trifluoromethyl)fluorophenylmethyl, fluoro(methoxy)phenylmethyl, trifluoromethoxyphenylethyl, phenylphenylethyl, phenylmethylpropyl, methoxyphenylethyl, ethoxyphenylethyl, cylcopropylmethoxyphenylethyl, phenylmethoxyphenylethyl, or phenyloxyphenylethyl.
10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen.
11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is hydrogen.
12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is C 1 -C 4 alkyl, and the alkyl is substituted with at least one halogen.
13. The compound of claim 12 , or a pharmaceutically acceptable salt thereof, wherein the halogen is fluoro, and R 4 is CH 2 F, CHF 2 , or CF 3 .
14. The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein R 4 is CF 3 .
15. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.